ArticleScience advances2026

Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance.

Fang-Tsyr Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.